Clinical Trials Browser

Endometrial Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Advanced Endometrial Cancer

Uterine Cervical Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

Uterine Cervical Neoplasms

Platinum-Refractory Fallopian Tube Carcinoma

Ovarian Neoplasms

Uterine Cervical Neoplasms

Fallopian Tube Neoplasms

Platinum-resistant Ovarian Cancer

Uterine Cervical Neoplasms, Lymphatic Metastasis

Gestational Trophoblastic Disease

Endometrial Neoplasms

Uterine Cervical Neoplasms

Uterine Cervical Neoplasms, HIV Infections

Endometrial Neoplasms

Carcinosarcoma, Ovarian Neoplasms

Endometrial Neoplasms

Ovarian Neoplasms

Uterine Cervical Dysplasia

Endometrial Neoplasms

Ovarian Neoplasms, Recurrence

Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms

Endometrial Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms

Peritoneal Neoplasms

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Endometrial Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pleural Effusion, Malignant

Ovarian Neoplasms

Uterine Cervical Neoplasms

Uterine Cervical Dysplasia

Breast Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms

Neoplasms, Ovarian Neoplasms, Recurrence

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Peritoneal Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

Treatment for Metastatic or Locally Advanced Cervical Cancer

Endometrial Neoplasms

Endometrial Neoplasms

Clinical Trials

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Non-Viral TCR Gene Therapy

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

APX005M

ITTACC

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer

CERAD-IMMUNE

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Curcumin in Advanced Cervical Cancer

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

Study of FP-1039 in Subjects With Endometrial Cancers

PRECISE

PANDA

DUETTE

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes

HIPEC

NICER

18F-CP18 Imaging Studies for Cancer Treatment With Birinapant

MaRuC

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Improving Tumor Oxygenation in Cervical Cancer

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients

Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Toremifene in Treating Patients With Ovarian Cancer

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer

Lenvatinib in Second Line Endometrial Carcinoma

Endometrial Cancer Biomarker Changes Following Exposure to Metformin